PE20020445A1 - Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de eter de monoaminoacido y diaminoacido de precursor de fosfato de combretastina a-4 - Google Patents
Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de eter de monoaminoacido y diaminoacido de precursor de fosfato de combretastina a-4Info
- Publication number
- PE20020445A1 PE20020445A1 PE2001000927A PE2001000927A PE20020445A1 PE 20020445 A1 PE20020445 A1 PE 20020445A1 PE 2001000927 A PE2001000927 A PE 2001000927A PE 2001000927 A PE2001000927 A PE 2001000927A PE 20020445 A1 PE20020445 A1 PE 20020445A1
- Authority
- PE
- Peru
- Prior art keywords
- acid
- salts
- monoamino
- diamino
- combretastin
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 5
- 239000002243 precursor Substances 0.000 title abstract 3
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical class C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 title abstract 2
- -1 DIAMINE SALTS Chemical class 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 150000001413 amino acids Chemical group 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 abstract 1
- 229960005537 combretastatin A-4 Drugs 0.000 abstract 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23256800P | 2000-09-14 | 2000-09-14 | |
| US25192100P | 2000-12-07 | 2000-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020445A1 true PE20020445A1 (es) | 2002-05-18 |
Family
ID=26926130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000927A PE20020445A1 (es) | 2000-09-14 | 2001-09-14 | Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de eter de monoaminoacido y diaminoacido de precursor de fosfato de combretastina a-4 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6670344B2 (https=) |
| EP (1) | EP1320534B1 (https=) |
| JP (2) | JP4149804B2 (https=) |
| KR (1) | KR100858464B1 (https=) |
| CN (1) | CN100338077C (https=) |
| AR (1) | AR030727A1 (https=) |
| AT (1) | ATE293630T1 (https=) |
| AU (2) | AU785183B2 (https=) |
| BR (1) | BRPI0107210B1 (https=) |
| CA (1) | CA2422359C (https=) |
| DE (1) | DE60110249T2 (https=) |
| EE (1) | EE200200249A (https=) |
| ES (1) | ES2241872T3 (https=) |
| HK (1) | HK1052356B (https=) |
| HU (1) | HU229055B1 (https=) |
| IL (3) | IL149601A0 (https=) |
| MX (1) | MXPA03002209A (https=) |
| NO (1) | NO329973B1 (https=) |
| NZ (1) | NZ524926A (https=) |
| PE (1) | PE20020445A1 (https=) |
| PT (1) | PT1320534E (https=) |
| RS (1) | RS50309B (https=) |
| SK (1) | SK287117B6 (https=) |
| TW (1) | TWI250163B (https=) |
| UY (1) | UY26935A1 (https=) |
| WO (1) | WO2002022626A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019944D0 (en) * | 2000-08-15 | 2000-09-27 | Angiogene Pharm Ltd | Compositions with vascular damaging activity |
| US20050153939A1 (en) * | 2003-09-10 | 2005-07-14 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
| WO2002086869A1 (en) * | 2001-04-19 | 2002-10-31 | Sony Corporation | Digital recording/reproducing apparatus |
| NZ575466A (en) * | 2001-07-13 | 2011-01-28 | Oxigene Inc | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| US20040229960A1 (en) * | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| US20090137687A1 (en) * | 2003-02-28 | 2009-05-28 | Oxigene, Inc. | Compositions and Methods With Enhanced Therapeutic Activity |
| CN100365000C (zh) * | 2003-09-18 | 2008-01-30 | 雍智全 | Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用 |
| CA2550660C (en) | 2003-12-23 | 2011-03-15 | Schering-Plough Ltd. | Florfenicol prodrug having improved water solubility |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| EP1896391B1 (en) | 2005-06-14 | 2015-08-12 | Baylor University | Combretastatin analogs with tubulin binding activity |
| CN1907989B (zh) * | 2005-08-02 | 2011-08-17 | 浙江天皇药业有限公司 | 毛兰素盐及其制备方法和包含其的药物组合物 |
| CA2633010A1 (en) * | 2005-12-19 | 2007-06-28 | Methylgene Inc. | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
| SI2007362T1 (sl) | 2006-04-04 | 2018-12-31 | Kg Acquisition Llc | Peroralne odmerne oblike, ki vključujejo antitrombocitno sredstvo in inhibitor kisline |
| WO2008001204A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal compositions of pramipexole having enhanced permeation properties |
| US8796330B2 (en) * | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| EP1973872A4 (en) | 2006-12-19 | 2012-05-09 | Methylgene Inc | HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF |
| US20090012325A1 (en) * | 2007-02-22 | 2009-01-08 | Ajith Manage | Methods for preparing phosphoric acids of combrestastatin and derivatives thereof |
| US20080214509A1 (en) * | 2007-03-02 | 2008-09-04 | Robert Kerbel | Methods for enhancing the efficacy of vascular disrupting agents |
| EP2178512B1 (en) * | 2007-06-22 | 2011-03-09 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
| DK2170292T3 (da) * | 2007-06-22 | 2014-04-07 | Bristol Myers Squibb Holdings Ireland | Atazanavirholdige sammensætninger i tabletform |
| SI2178513T1 (sl) * | 2007-06-22 | 2011-05-31 | Bristol Myers Squibb Co | Tabletni sestavki vsebujoäśi atazanavir |
| ES2360336T3 (es) * | 2007-06-22 | 2011-06-03 | Bristol-Myers Squibb Company | Composiciones en comprimidos que contienen atazanavir. |
| DK2219451T3 (en) * | 2007-11-21 | 2015-01-12 | Oxigene Inc | A method for the treatment of hematopoietic neoplasms |
| CN102757338B (zh) * | 2012-02-29 | 2015-02-25 | 郑州泰基鸿诺药物科技有限公司 | 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途 |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| EP3337495A4 (en) | 2015-08-18 | 2019-04-10 | Mateon Therapeutics, Inc. | USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| WO2018144910A1 (en) | 2017-02-02 | 2018-08-09 | Bioventures, Llc | Methods of protecting against neurodegeneration |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2025250885A1 (en) * | 2024-05-31 | 2025-12-04 | Oncotelic, Inc. | In situ tumor-infiltrating lymphocyte therapeutics for cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| DE3438386A1 (de) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | Phosphorsaeurevinylbenzylester, ihre herstellung und verwendung |
| GB9106177D0 (en) | 1991-03-22 | 1991-05-08 | Aston Molecules Ltd | Substituted diphenylethylenes and analogues or derivatives thereof |
| US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| DE19506885A1 (de) | 1995-02-17 | 1996-08-22 | Schering Ag | Neue Borneolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| WO1999035159A1 (en) * | 1998-01-08 | 1999-07-15 | Brigham & Women's Hospital, Inc. | Lymphoma/leukemia oncogene, oncoprotein and methods of use |
| JP2002500227A (ja) * | 1998-01-09 | 2002-01-08 | アリゾナ ボード オブ リーゼンツ | コンブレタスタチンａ−４プロドラッグとそのトランス異性体 |
| GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| GB9903403D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Substituted stilbene compounds with vascular damaging activity |
| GB0019944D0 (en) | 2000-08-15 | 2000-09-27 | Angiogene Pharm Ltd | Compositions with vascular damaging activity |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
-
2001
- 2001-09-11 US US09/950,500 patent/US6670344B2/en not_active Expired - Lifetime
- 2001-09-12 MX MXPA03002209A patent/MXPA03002209A/es active IP Right Grant
- 2001-09-12 DE DE60110249T patent/DE60110249T2/de not_active Expired - Lifetime
- 2001-09-12 CA CA002422359A patent/CA2422359C/en not_active Expired - Fee Related
- 2001-09-12 HK HK03104615.4A patent/HK1052356B/zh not_active IP Right Cessation
- 2001-09-12 AU AU90771/01A patent/AU785183B2/en not_active Ceased
- 2001-09-12 TW TW090122636A patent/TWI250163B/zh not_active IP Right Cessation
- 2001-09-12 BR BRPI0107210-2A patent/BRPI0107210B1/pt not_active IP Right Cessation
- 2001-09-12 JP JP2002526877A patent/JP4149804B2/ja not_active Expired - Fee Related
- 2001-09-12 WO PCT/US2001/028401 patent/WO2002022626A1/en not_active Ceased
- 2001-09-12 AT AT01970806T patent/ATE293630T1/de active
- 2001-09-12 RS YUP-348/02A patent/RS50309B/sr unknown
- 2001-09-12 EE EEP200200249A patent/EE200200249A/xx unknown
- 2001-09-12 HU HU0204423A patent/HU229055B1/hu not_active IP Right Cessation
- 2001-09-12 CN CNB018031404A patent/CN100338077C/zh not_active Expired - Fee Related
- 2001-09-12 KR KR1020027006168A patent/KR100858464B1/ko not_active Expired - Fee Related
- 2001-09-12 NZ NZ524926A patent/NZ524926A/en not_active IP Right Cessation
- 2001-09-12 PT PT01970806T patent/PT1320534E/pt unknown
- 2001-09-12 IL IL14960101A patent/IL149601A0/xx active IP Right Grant
- 2001-09-12 SK SK672-2002A patent/SK287117B6/sk not_active IP Right Cessation
- 2001-09-12 EP EP01970806A patent/EP1320534B1/en not_active Expired - Lifetime
- 2001-09-12 ES ES01970806T patent/ES2241872T3/es not_active Expired - Lifetime
- 2001-09-13 AR ARP010104346A patent/AR030727A1/es unknown
- 2001-09-13 UY UY26935A patent/UY26935A1/es not_active Application Discontinuation
- 2001-09-14 PE PE2001000927A patent/PE20020445A1/es not_active Application Discontinuation
-
2002
- 2002-05-12 IL IL149601A patent/IL149601A/en unknown
- 2002-05-13 NO NO20022270A patent/NO329973B1/no not_active IP Right Cessation
-
2003
- 2003-09-10 US US10/660,439 patent/US6855702B2/en not_active Expired - Lifetime
-
2006
- 2006-06-04 IL IL176088A patent/IL176088A0/en unknown
-
2007
- 2007-01-19 AU AU2007200218A patent/AU2007200218A1/en not_active Abandoned
-
2008
- 2008-05-07 JP JP2008121719A patent/JP2008195740A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020445A1 (es) | Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de eter de monoaminoacido y diaminoacido de precursor de fosfato de combretastina a-4 | |
| US6391325B1 (en) | Use of nitrogen-containing complexing agents for deodorization and antimicrobial treatment of the skin and textile fibre materials | |
| US20050255172A1 (en) | Hydrogen peroxide-based skin disinfectant | |
| GB2553158A (en) | Surfactant-containing cleansing agents with at least three different preservatives | |
| BRPI0720201A2 (pt) | Composições suaves para desinfecção da pele | |
| RU2010126103A (ru) | Способ получения адапаленовых гелей | |
| ES8402558A1 (es) | "un procedimiento para preparar una n-(4-(3-aminopropil)-aminobutil)-2-(acido-guanidino-graso-amido)-etanamida sustituida en posicion 2". | |
| BR112015014260B1 (pt) | Método para indicar a liberação de um agente antibacteriano ou para indicar uma quantidade de tempo para a limpeza da pele | |
| MX2024007242A (es) | Lipido y composicion utilizada para la administracion. | |
| PA8485601A1 (es) | Azalidas de 13 miembros y su uso como agentes antibioticos. | |
| CN114146012A (zh) | 一种抗菌去屑洗发水及其制备方法 | |
| ES2147629T3 (es) | Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene. | |
| SE0201658D0 (sv) | Immediate release pharmaceutical formulation | |
| BG106602A (en) | Formulation of substituted benzimidazoles | |
| KR100457991B1 (ko) | 모발보호제품용조성물 | |
| MX2023009166A (es) | Derivados de quinoxalina y sus usos. | |
| ATE539761T1 (de) | Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion | |
| AR031074A1 (es) | Una composicion farmaceutica que comprende un derivado de benzamida como ingrediente activo | |
| US20020193322A1 (en) | Method of preparing physiologically acceptable aqueous solutions, and solutions thus obtained | |
| ES2357379T3 (es) | Composición detergente. | |
| CO6270205A2 (es) | Formulacion que contiene un compuesto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo | |
| CN109589272A (zh) | 阳离子表面活性剂的新应用以及抵荧光美容品 | |
| PE20060741A1 (es) | Procedimiento de preparacion de salicilamidas n-sustituidas | |
| IL26285A (en) | Preparations regulate the growth of plants that include the conversion of converted acid | |
| BR0207475A (pt) | Processo para a preparação ácido d-pantotênico e /ou de seus sais, e, composição para uso como suplemento de ração de animal e/ou aditivo de ração de animal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |